| Discipline | Oncology |
|---|---|
| Language | English |
| Edited by | Mels Sluyser |
| Publication details | |
| History | 1990–present |
| Publisher | Lippincott Williams & Wilkins |
| Frequency | 10/year |
| Impact factor | 1.784 (2014) |
| Standard abbreviations ISO 4 (alt) · Bluebook (alt) NLM (alt) · MathSciNet (alt  ) | |
| ISO 4 | Anti-Cancer Drugs |
| Indexing CODEN (alt · alt2) · JSTOR (alt) · LCCN (alt) MIAR · NLM (alt) · Scopus | |
| ISSN | 0959-4973 (print) 1473-5741 (web) |
| Links | |
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy.
References
- "Journal Homepage". Archived from the original on 2003-11-10. Retrieved 2010-02-17.
External links
  | This article about an oncology journal is a stub. You can help Misplaced Pages by expanding it. See tips for writing articles about academic journals. Further suggestions might be found on the article's talk page. |